Characteristics of included studies
| Dobrocky et al24 | Goyal et al12 | Messer et al25 | Saito et al22 | Sarraj et al23 | Seners et al10 | |
| Countries | Switzerland, Germany | North America, Europe, Asia | Germany | Japan | USA, Spain | France |
| Study duration (dates) | 2005–2020 | 2013–2017 | 1998–2015 | 2014–2016 | 2012–2017 | 2006–2018 |
| NIHSS score | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| Active group | EVT±IVT | EVT±IVT | EVT±IVT | EVT±IVT | EVT±IVT | EVT±IVT |
| Comparator group | IVT | BMM (including IVT) | IVT | IVT | BMM (including IVT) | IVT |
| Outcome available in vessel occlusion sites | M2 | Proximal ICA or M1 and M2 | Proximal ICA or M1 | Proximal ICA or M1 | Proximal ICA or M1, M1, and M2 | M1 and M2 |
| ICA or M1 occlusions | 0 | 172 | 26 | 81 | 122 | 252 |
| M2 occlusions | 164 | 79 | 0 | NA | 77 | 346 |
| Prospective study design | No | No | No | No | No | Yes |
| Comparable group available | Yes | Yes | Yes | Yes | Yes | Yes |
| Adjustment of confounders | No | No | No | No | No | No |
| Documented loss of follow-up rate | No | No | No | No | No | No |
BMM, best medical management; EVT, endovascular therapy; ICA, internal carotid artery; IVT, intravenous thrombolysis; M1, first segment of middle cerebral artery; M2, second segment of middle cerebral artery; NA, not available.